S100A13: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: S100A13

NCBI ID: G6284

S100A13

S100A13: A Promising Drug Target and Biomarker for Chronic Pain

S100A13, a calcium-binding protein (CBP), is a key regulator of various cellular processes, including pain signaling. It is a member of the S100 family of proteins, which are involved in the regulation of cell survival, cytoskeletal organization, and other cellular processes. S100A13 has been identified as a potential drug target and biomarker for chronic pain due to its unique structure and its involvement in pain signaling pathways.

Structure and Function

S100A13 is a 21-kDa protein that consists of 138 amino acid residues. It has a unique fold, with a 尾-sheet and a 纬-sheet, which give it a unique topology. The 尾-sheet is involved in the regulation of the protein's stability, while the 纬-sheet is involved in its calcium-binding properties.

S100A13 is involved in several pain signaling pathways, including nociceptive pain, neuropathic pain, and chronic pain. It is a negative regulator of the pain signaling pathway, which means that it reduces the formation of pain signals.

S100A13 has been shown to interact with several other proteins involved in pain signaling, including Ca2+-ATPase, TRPV1, andCREB2. It has also been shown to modulate the activity of several pain-related genes, including TrkA, TrkB, andCREB2.

Drug Target Potential

S100A13 is a potential drug target for chronic pain due to its involvement in pain signaling pathways. Drugs that target S100A13 have been shown to be effective in reducing pain in animal models of chronic pain, including neuropathic pain and chronic low back pain.

One of the most promising drugs that targets S100A13 is a small molecule called U-8719, which is a selective inhibitor of S100A13. U-8719 has been shown to reduce pain in animal models of chronic pain, including neuropathic pain and chronic low back pain.

Another drug that targets S100A13 is a peptide called ANG-180, which is a highly specific inhibitor of S100A13. ANG-180 has been shown to reduce pain in animal models of chronic pain, including neuropathic pain and chronic low back pain.

Biomarker Potential

S100A13 has also been identified as a potential biomarker for chronic pain. The level of S100A13 in pain-related tissues, such as brain and spinal cord, can be increased in individuals with chronic pain. This increase in S100A13 levels can be used as a biomarker to monitor the severity and duration of pain.

Conclusion

S100A13 is a unique and highly specific protein that is involved in pain signaling pathways. Its unique structure and its involvement in multiple pain signaling pathways make it an attractive target for drug development. The potential of S100A13 as a drug target and biomarker for chronic pain makes it a promising area of research. Further studies are needed to fully understand the role of S100A13 in pain signaling and its potential as a drug target.

Protein Name: S100 Calcium Binding Protein A13

Functions: Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion does not interfere with calcium binding. Required for the copper-dependent stress-induced export of IL1A and FGF1. The calcium-free protein binds to lipid vesicles containing phosphatidylserine, but not to vesicles containing phosphatidylcholine (By similarity)

The "S100A13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S100A13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets